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A prospective phase II multicenter trial was performed with the aim to obtain less than 25% nonrelapse
mortality (NRM) after unrelated cord blood transplantation (UCBT) for adults with acute myeloid leukemia
(AML) using a reduced-intensity conditioning regimen (RIC) consisting of total body irradiation (2 Gy),
cyclophosphamide (50 mg/kg), and ﬂudarabine (200 mg/m2). From 2007 to 2009, 79 UCBT recipients were
enrolled. Patients who underwent transplantation in ﬁrst complete remission (CR1) (n ¼ 48) had a higher
frequency of unfavorable cytogenetics and secondary AML and required more induction courses of chemo-
therapy to achieve CR1 compared with the others. The median infused total nucleated cells (TNC) was 3.4 
107/kg, 60% received double UCBT, 77% were HLA mismatched (4/6), and 40% had major ABO incompatibility.
Cumulative incidence of neutrophil recovery at day 60 was 87% and the cumulative incidence of 100-day
acute graft-versus-host disease (II to IV) was 50%. At 2 years, the cumulative incidence of NRM and relapse
was 20% and 46%, respectively. In multivariate analysis, major ABO incompatibility (P ¼ .001) and TNC (<3.4 
107/kg; P ¼ .001) were associated with increased NRM, and use of 2 or more induction courses to obtain CR1
was associated with increased relapse incidence (P ¼ .04). Leukemia-free survival (LFS) at 2 years was 35%,
and the only factor associated with decreased LFS was secondary AML (P ¼ .04). In conclusion, despite the
decreased NRM observed, other RIC regimens with higher myelosuppression should be evaluated to decrease
relapse in high-risk AML. (EUDRACT 2006-005901-67).
 2015 American Society for Blood and Marrow Transplantation.METHODSINTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) using a high-dose or myeloablative conditioning
(MAC) regimen is a curative option for the treatment of acute
myeloid leukemia (AML), especially in young adult patients.
However, this procedure is not often used for older patients
and/or those patients with comorbidities because of the
higher mortality rates related to transplantation in these
populations. Non-myeloablative and reduced-intensity con-
ditioning (RIC) regimens have been developed to minimize
the effects of toxicity and death of allogeneic HSCT, mainly
decreasing nonrelapse mortality (NRM) [1]. Nevertheless,
preparative regimens with greater antileukemic intensity
and with minimal extramedullary toxicity should be better
evaluated in patients with AML [2,3].
Many studies have shown that allogeneic RIC, compared
withMAC, HSCT inpatientswith AMLdecreasesNRM, but it is
associated with an increased relapse rate and, because of this
balance, it does not impact leukemia-free survival (LFS) [4,5].
A MAC regimen before single or double unrelated cord
blood transplantation (UCBT) has been frequently used in
adult patients with leukemia, with high morbidity and
mortality rates (34% to 57%), probably due to delayed he-
matopoietic recovery [6-10]. Therefore, strategies to
decrease mortality and improve engraftment, such as use of
RIC, double UCBT, cord blood intrabone infusion, and in vitro
expansion [8,11-15] have been sought.
These strategies are under investigation and may mini-
mize the high incidence of NRM related to the delayed
neutrophil recovery and toxicity seen after MAC UCBT. The
use of single or double UCBT associated with low-dose total
body irradiation (TBI) (2 Gy), cyclophosphamide, and ﬂu-
darabine (TCF) showed the beneﬁts of obtaining a prompt
and complete neutrophil recovery and decreased mortality
related to transplantation [11,16-18]. However, outcomes
after RIC UCBT using TCF have been analyzed for patients
with various hematological malignancies who underwent
transplantation in remission or advanced phase of the dis-
ease [18]; nonetheless, the use of such conditioning regimen
for patients with AML needs further investigation.
With the aim of obtaining a cumulative incidence of NRM
lower than 25% after RIC UCBT using TCF in AML patients, the
Societé Française de Greffe de Moelle Osseuse et Therapie
Cellulaire and Eurocord conducted a phase II multicenter
prospective trial.Study Design and Patients
The primary objective of this prospective, multicenter phase II trial
was to obtain a cumulative incidence of NRM at 2 years lower than 25%
using an established conditioning regimen, namely TCF, in AML patients.
Criteria of inclusion were the following: patients between 15 and 65
years of age with de novo or secondary AML for whom an HLA-identical
related or unrelated hematopoietic stem cell donor, deﬁned as 10/10 or 9/
10 HLA match (considering an allelic HLA typing of class I and class II),
were not available. Patients or their legal guardians gave their informed
consent to participate in the study, according to the Declaration of Hel-
sinki. Exclusion criteria included creatinine clearance below 50 mL/
minute, left ventricular ejection fraction below 40%, severe abnormalities
of functional respiratory tests, bilirubin level higher than twice the limits
of normal range, alanine aminotransferase level more than 4 times the
upper limits of normal range, poorly controlled hypertension, and a
Karnofsky score <70.
Patients were recruited in 23 centers of the Societé Française de
Greffe de Moelle Osseuse et Therapie Cellulaire between October 2007
and August 2009 and were followed for 2 years after inclusion. This study
was approved by the internal review board of Hôtel-Dieu Assistance
Publique-Hôpitaux de Paris.Procedures
Conditioning regimen and graft-versus-host disease prophylaxis
The conditioning regimen, consisted of cyclophosphamide 50 mg/kg/
day on day -6, ﬂudarabine 40 mg/m2/day from day-6 to day-2, and TBI at 2
Gy at day-1.
Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine
with mycophenolate mofetil. Cyclosporine was started at day-3 and main-
tained until day þ100, then it was slowly tapered until 6 months and
stopped in absence of GVHD. Mycophenolate mofetil was started at day-3 at
30 mg/kg/day and stopped at day þ30.
Supportive care
Lenograstim was started at day þ1 at 150 mg/m2/day until achieving an
absolute neutrophil count (ANC) .5  109/L for 3 consecutive days. Then, it
was given every 2 days until recovery was conﬁrmed. All patients were
treated in laminar air ﬂow rooms and received oral antibiotics against
gram-positive bacteria (oracillin, amoxicillin, or josamycine), ﬂuconazole
400 mg per day, and valacyclovir or acyclovir for herpes simplex and zoster
and cytomegalovirus (CMV) prophylaxis. Fluconazole was stopped when
patients had an ANC above 1  109/L and were off corticosteroids. Oral
antibiotics were continued for 1 year after transplantation in patients
without any sign of chronic GVHD or until discontinuation of immuno-
suppressive treatment. Prophylaxis against Pneumocystis jirovecii and/or
toxoplasmosis (trimethoprim/sulfamethoxazole or sulfadoxine/pyrimeth-
amine, respectively) was started after neutrophil recovery and continued
for a minimum of 6 months or until discontinuation of immunosuppressive
treatment. Patients were tested once each week during the ﬁrst 100 days
after UCBT by real-time PCR for CMV and Epstein-Barr virus, toxoplasmosis,
human herpesvirus 6, and adenovirus in case of any clinical sign of viral
infection. Assessment for Aspergillus infection using serum galactomanan
test was performed once each week in the ﬁrst 100 days.
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The minimum total nucleated cell (TNC) dose required for a single unit
UCBT was 3  107/kg before freezing and the maximum HLA disparity
permitted was 4/6 between patient and units. In case of a double-unit UCBT,
there was no requirement for a minimum cell dose of each unit. The total
amount of nucleated cells of both units should be more than 3  107/kg
before freezing. Also, an HLA 4/6 matching was recommended between the
units in case of double cord blood transplantation. HLA was deﬁned by low
resolution for HLA-A and-B and high resolution for HLA-DRB1; the highest
HLA disparity between cord blood and patients was taken into consideration
in double cord blood transplantation. ABO was classiﬁed as the highest ABO
incompatibility between cord blood and patients in case of double UCBT.
Deﬁnitions of Endpoints
Overall survival (OS) was calculated from the date of UCBT until death or
last observation alive. LFS was calculated from the date of UCBT until relapse
or last disease free follow-up. Relapse and death from any cause were
considered events. NRM was deﬁned as death without prior relapse.
Neutrophil recovery was deﬁned as achieving ANC .5  109/L for 3
consecutive days. Full donor chimerism was deﬁned as 95% leukocytes of
donor origin in peripheral blood or marrow samples, measured by different
techniques, according to transplantation centers. Autologous reconstitution
was deﬁned as 95% leukocytes of recipient origin. Mixed chimerism was
deﬁned by the presence of >5% but <95% of leukocytes of donor origin. The
diagnosis and grading of acute and chronic GVHD was assigned by the
transplantation centers using standard criteria [19,20].
Sample Size and Justiﬁcation
The primary objective of this multicenter phase II trial was to obtain a
cumulative incidence of NRM lower than 25% based on information gath-
ered from previous studies; 1 of them showing an NRM of 45% after UCBT
using a MAC regimen for adults with hematological malignancies [8] and
another showing an NRM of 25% [16,17] in UCBT recipients given RIC before
transplantation. Therefore, with a type I and type II error rate of 5% and the
hypothesis of decreasing the NRM from 45% to 25%, from a 2-sided test
based on 1 sample, at least 76 patients enrolled in the study was required.
Statistical Analysis
Median values and ranges were used for continuous variables and
percentages were used for categorical variables. Patient-, disease-, and
transplantation-related variables of the groups (CR1 and others) were
compared using chi-square or exact Fisher’s test for categorical variables
and Mann-Whitney test for continuous variables. The distributions of OS
and LFS were calculated using the Kaplan-Meier [21] method and then
compared by the log-rank test. The cumulative incidence of neutrophil
engraftment, grade II to IV acute and chronic GVHD, relapse, and NRMwere
calculated within a competing risks setting, where deaths before the event
of interest were considered competing risks. The following variables were
tested in the univariate analyses: age and weight (introduced as contin-
uous variables) at transplantation, gender, CMV serology before trans-
plantation, comorbidity index, cytogenetic risk, French-American-British
classiﬁcation (FAB), de novo or secondary AML, number of courses of in-
duction to achieve CR, extramedullary leukemia, time intervals between
diagnosis and CR1 and between CR1 and UCBT, graft source (single or
double), number of nucleated cells infused per kilogram of body weight,
number of HLA disparities, and ABO compatibility.
Multivariate analyses were performed using Cox proportional hazards
regression model [22] for LFS and OS, and the cause-speciﬁc Cox propor-
tional hazards model was used for neutrophil engraftment, grade II to IV
acute and chronic GVHD, relapse, and NRM. Variables that reached a P value
of .15 in the univariate analyses were then included in the multivariable
models, as well as the propensity to have reached CR1. Indeed, given the low
sample size, we summarized the predictive information of the CR1 outcome
using the linear score derived from the multivariable logistic model,
including median number of TNC infused (3.4  107/kg), FAB classiﬁcation,
cytogenetics, time from diagnosis to CR1, and comorbidity score. Variable
selection was based on a stepwise procedure at the .05 level.
Statistical analyses were performed with SAS 9.3 (SAS Inc, Cary, NC) and
R (http://www.R-project.org/) software.
RESULTS
Patient’s Characteristics
Characteristics of 79 patients are listed in Table 1. The
median age at UCBT was 51 years (range, 15 to 65), median
weight was 65 kg (range, 49 to 105), 53% of patients were
female, and 49% had positive CMV serology before UCBT. Thecomorbidity score [5] was 1 in 16%, 2 in 12%, and 3 or higher
in 24%; 48% of the patients had no comorbidities. Cytoge-
netics was normal in 33 patients (52%); of those 1 of 33 were
Fms-like tyrosine kinase 3 internal tandem duplication
(FLT3/ITD) positive and abnormal in 48%, including 36% with
a complex karyotype and/or abnormality of chromosomes 5,
7, 11 and inversion of chromosome 3. Nine (14%) patients had
previously undergone transplantation with autologous pe-
ripheral blood stem cells.
Forty-eight patients underwent transplantation in CR1,
30 in CR2, and 1 in CR4. Table 1 also lists patients-, disease-,
and transplantation-related factors by disease status at
transplantation and the statistical differences between pa-
tients who underwent transplantation in CR1 and other
disease status (CR2 or more).
Patients in CR1 with favorable cytogenetics were not
offered transplantation, with the exception of 1 patient who
underwent transplantation in CR1with favorable cytogenetics
because CR was achieved only after 3 courses of chemo-
therapy. Compared with patients who underwent trans-
plantation in CR2 or more, CR1 patients had higher frequency
of unfavorable cytogenetics (60%), and among those, 19% had
secondary leukemia. Almost 50% of patients who underwent
transplantation in CR1 achieved remission after 2 courses of
induction treatment. The time between diagnosis and trans-
plantationwas 6.6 (range, 5.6 to 8) and 19months (range,13.8
to 23) for the ﬁrst and second remission groups, respectively.
The majority of patients received 2 cord blood units. After
thawing the cord blood units, patients who underwent
transplantationwith a single CBU received a median number
of nucleated cells of 2.92  107/kg and a median of .92
CD34  105/kg. Patients who underwent transplantation
with 2 CBU received 3.5  107/kg and 1.1  105/kg, respec-
tively. Regarding HLA compatibility, 2% of the units were HLA
matched, 21% were 5/6, and 77% were 4/6. ABO major in-
compatibility was observed in 44% of the patients (in double
cord blood, the highest incompatibility was considered).
Outcomes
Neutrophil and platelet recovery
Seventy patients achieved neutrophil counts >500/mL.
The cumulative incidence of neutrophil recovery at day þ60
was 89%. Median time for recovery was 15 days (range, 4 to
53). Nine patients did not engraft: 2 died in aplasia at
day þ23 (central nervous system hemorrhage) and dayþ116
(after a second transplantation), 4 died after autologous
reconstitution and relapse, 2 were alive with autologous
reconstitution at last follow-up (more than 2 years after
transplantation), and 1 was alive after a second trans-
plantation with a mismatched related donor.
In univariable analyses for neutrophil recovery, younger
patients (continuous variable) (hazard ratio [HR], 1.02; 95%
conﬁdence interval [95%CI],1 to 1.03;P¼ .04), higher cell dose
(continuous variable) (HR, 1.28; 95% CI, 1.02 to 1.61; P ¼ .03),
positive CMV serology before transplantation (HR, 1.77; 95%
CI,1.09 to 2.86; P¼ .02), and undergoing transplantationwith
a major incompatibility ABO graft (HR, 1.75; 95% CI, 1.07 to
2.85; P ¼ .026) were associated with greater neutrophil re-
covery. All factors above were independent risk factors for
neutrophil recovery in a multivariable model. There was no
statistical difference for patients who underwent trans-
plantation with a single or double UCBT. Forty-nine patients
achieved platelet counts >20,000/mL at a median time of 36
days (range, 6 to 77). At day 180, the cumulative incidence of
platelet recovery was 62%.
Table 1
Patient, Disease, Transplantation, and Donor-related Factors: Total Number by Disease Status at Transplantation
Characteristics CR1 Patients (n ¼ 48) >CR1 Patients (n ¼ 31) P Value Total (n ¼ 79)
n % or median (95% CI) n % or median (95% CI) n % or median (95% CI)
CR1 >CR1
Age at UCBT 48 51.4 (36.7-58.4) 31 48.2 (35.1-57.0) .35 79 51.0 (35.1-58.0)
Gender
Male 19 39.5% 18 58.1% .17 37 46.8%
Female 29 60.4% 13 41.9% 42 53.2%
CMV serology
Negative 21 43.8% 19 61.3% .17 40 50.6%
Positive 27 56.3% 12 38.7% 39 49.4%
Comorbidity index (Sorror)
0 20 43.5% 17 54.8% .57 37 48.1%
1 7 15.2% 5 16.1% 12 15.6%
2 19 41.3% 9 29.0% 28 36.4%
NA 2 0 2
Weight
Kg 47 64.0 (56.5-76.0) 31 66.0 (58.5-73.5) .65 78 65 (57.3-74.8)
Previous fungal Infection
Yes 11 22.9% 6 19.4% 17 21.5%
FAB classiﬁcation
M0,M1,M2 17 35.4% 18 58.1% .003 35 44.3%
M4 9 18.8% 10 32.3% 19 24.1%
Others 22 45.8% 3 9.7% 25 31.7%
Secondary AML*
No 39 81.3% 26 83.9% 1.00 65 82.3%
Yes 9 18.8% 5 16.1% 14 17.7%
Cytogenetic risk
Favorable 1 2.1% 5 16.1% .01 6 7.6%
Intermediate 18 37.5% 17 54.8% 35 44.3%
Unfavorable 29 60.4% 9 29.0% 38 48.1%
Interval from diag. to UCBT
Months 47 6.6 (5.6-8.0) 30 18.9 (13.4-23.2) <.0001 77 8.0 (5.8-16.3)
Interval from last CR to UCBT 48 4.6 (3.5-6,0) 28 3.05 (2.3-4.2) .01 76 4.0 (2.5-5.3)
Interval from diag. to CR1
Days 47 57.0 (41.5-81.5) 27 41.0 (32.0-51.5) .02 74 48.0 (38.0-67.8)
No. of inductions
1 20 51.3% 19 86.4% .02 39 63.9%
2 14 35.9% 3 13.6% 17 27.9%
3 5 12.8% 0 0% 5 8.2%
NA 9 9 18
Extramedullary involvement
No 41 85.4% 30 96.8% .14 71 89.9%
Yes 7 14.6% 1 3.2% 8 10.1%
Year of transplantation
2007 1 2.1% 3 9.7% .05 4 5.1%
2008 19 39.9% 18 58.1% 37 46.8%
2009 28 58.3% 10 32.3% 38 48.1%
Type of graft
Single 15 31.3% 11 35.5% .81 26 32.9%
Double 33 68.8% 20 64.5% 53 67.1%
TNC  107/kg 48 3.5 (2.8-4.2) 31 3.5 (3.1-3.8) .64 79 3.5 (3.0-4.1)
CD34/kg  105/kg infused 48 .1 (.07-.14) 31 .1 (.08-.178) .21 79 .1 (.08-.15)
CD3/kg  106/kg infused 29 5.6 (4.2-7.0) 20 5.3 (3.8-6.3) .89 49 5.6 (3.8-7.0)
CFU-GM  104/kg infused 31 1.0 (.3-1.6) 20 1.4 (.2-3.8) .45 51 1.0 (.23-2.16)
HLA match
5/6 or 6/6 12 25.0% 6 19.4% .60 18 22.8%
4/6 or 3/6 36 75.0% 25 80.7% 61 77.2%
ABO
Matched 15 31.3% 11 35.5% .53 26 32.9%
Minor 13 27.1% 5 16.1% 18 22.8%
Major 20 41.7% 15 48.4% 35 44.3%
NA indicates not available; Diag indicates diagnosis; CFU-GM, colony forming unit-granulocyte and monocyte.
* Secondary AML to myeloproliferative disorder (n ¼ 1); myelodysplastic syndrome (n ¼ 6), and secondary myelodysplastic syndrome (n ¼ 7; breast cancer
n ¼ 4, previous autologous transplantation, for lymphoma ¼ 3).
Statistically signiﬁcant P values are shown in bold.
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engrafted at days þ30 and þ60 and months 3 and 6 after
transplantation. Full donor chimerism was observed in 47%
for single UCBT and 77% for double UCBT recipients at
day þ30, and in 75% and 92%, at day 60þ, respectively.Almost the same ﬁgures were observed at 3 and 6 months
after UCBT. Figure 1 shows the chimerism data by type of
graft (single, n ¼ 22; double, n ¼ 48) during different time
periods after UCBT. In the group of patients who underwent
transplantation with a single CB unit who had engrafted by
Figure 1. Chimerism data for patients who engrafted by single (left) and
double (right) UCBT, and the time period in which they engrafted.
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group of patients who underwent transplantation with a
double CB unit who had engrafted, full chimerism for most
patients was also observed at day þ60; however, dual
chimerism was observed during 3 months in few patients.
Acute and chronic GVHD
Acute GVHD was observed in 39 patients; 14 had grade I,
16 patients had grade II, 18 patients had grade III, and 1 pa-
tient had grade IV. The cumulative incidence of acute GVHD
(grades II to IV) at day þ100 was 50%  6% and 24%  3% for
grade III and IV. In univariate analyses, increased incidence of
acute GVHD was associated with ABO major incompatibilityFigure 2. (A) Cumulative incidence of nonrelapse mortality overall. (B) Incidence o
(C) by ABO compatibility.(HR, 2.21; 95% CI,1.04 to 4.7; P¼ .04). Inmultivariate analysis,
we did not ﬁnd any risk factor associated with acute GVHD.
Thirty-one patients had skin involvement (grade 1, n ¼ 4;
grade 2, n ¼ 15; and grade 3, n ¼ 12), 8 patients had liver
involvement (grade 2, n ¼ 5; grade 3, n ¼ 3), and 23 had
gastrointestinal involvement (grade 1, n ¼ 4; grade 2, n ¼ 8;
grade 3, n ¼ 7; and grade 4, n ¼ 4). GVHD treatment was
mainly steroids and it was associated with antithymocyte
globulin in 4 patients (grade 3 or 4) and with monoclonal
antibody in another patient (grade 4). Of the 19 patients
having grade 3 or 4 GVHD, 13 died, mostly of infections.
Chronic GVHD was diagnosed in 16 of 66 patients at risk:
12 had limited GVHD and 4 extensive GVHD.
NRM and causes of death
The median follow-up for survivors was 25 months. At
2 years, the cumulative incidence of NRM was 20.25%
(Figure 2A). Table 2 shows the risk factors for NRM in uni-
variate analyses. In multivariable analysis, 2 factors were
associatedwith increased risk ofNRM: lower TNC (<3.4107/
kg) (HR, 3.3; 95% CI, 1.1 to 8.3; P¼ .003) (Figure 2B) andmajor
ABO incompatibility (HR, 12.6; 95% CI, 2.77 to 57; P ¼ .001)
(Figure 2C). Sixteen patients died of transplantation-related
causes: 6 from GVHD, 4 of whom had associated infections
(sepsis, n ¼ 1; adenovirus and HHV6, n ¼ 1; CMV disease,
n ¼ 2) and 2 other causes. Causes of death for the remaining
10 patients were sepsis (n ¼ 1), central nervous system
hemorrhage (n ¼ 1), toxicities (n ¼ 4, multiorgan failure,
renal, and or cardiac failure), and 4 unknown or other causes.
Because ABO compatibility was an important factor
associated with NRM, we looked at causes of death by ABOf transplantation-related mortality according to TNC infused ( ;107/kg) and
Table 2
Univariable Analysis for Nonrelapse Mortality
Characteristics Values n HR 95% CI P Value
Age (continuous),
yr
79 1.01 (.97-1.04) .78
Gender Male 37 1.00
Female 42 1.14 (.42-3.06) .80
CMV status Neg 40 1.00
Pos 39 .59 (.21-1.62) .30
Comorbidity
index (Sorror)
0 37 1.00
1 12 2.03 (.48-8.50) .33
>¼2 28 1.92 (.61-6.04) .27
Weight
(continuous), kg
78 1.03 (1-1.07) .073
Disease status >CR1 31 1.00
CR1 48 1.31 (.48-3.62) .60
FAB classiﬁcation M0, M1,
or M2
35 1.00
M4 19 .52 (.14-1.97) .34
Others 25 .78 (.26-2.40) .67
Secondary AML No 65 1.00
Yes 14 1.58 (.45-5.58) .48
Cytogenetic risk Favorable 6 1.00
Intermediate 35 1.43 (.18-11.65) .74
Unfavorable 38 1.40 (.18-11.24) .75
Interval from
diag. to UCBT
77 .96 (.9-1.03) .26
Interval from
CR1 to UCBT
76 .98 (.79-1.23) .89
Days from
diag. to CR1
74 1.00 (1.00-1.01) .22
No. of inductions 1 39 1.00
2 17 .23 (.03-1.75) .15
3 5 3.35 (.68-16.46) .14
Extramedullary
involvement
No 71 1.00
Yes 8 0 (0-Inf) 1.00
Type of graft Single 26 1.00
Double 53 .99 (.34-2.86) .99
TNC infused 79 .84 (.47-1.48) .55
CD34/kg infused 79 .01 (0-56.60) .30
CD3/kg infused 49 1.04 (.81-1.33) .75
CFU-GM infused 51 .76 (.45-1.29) .31
HLA match 5/6 or 6/6 18 1.00
4/6 or 3/6 61 .82 (.27-2.56) .74
ABO compatibility Matched 26 1.00
Minor 18 1.90 (.12-30.33) .65
Major 35 12.08 (1.59-91.92) .02
ABO major
incompatibility
No 44 1.00
Yes 35 9.23 (2.10-40.62) .003
B. Rio et al. / Biol Blood Marrow Transplant 21 (2015) 445e453450compatibility. In fact, 1 patient died of infection associated
with graft failure, out of 26 patients given an ABO compatible
graft; 1 patient with graft failure died of hemorrhage, out
of 18 patients given a minor ABO mismatched graft, and
14 patients died of GVHD or complications (9 GVHD, 2
infections, and 3 toxicities) out of 35 given a major ABO-
incompatible graft.
Relapse
Thirty-seven patients relapsed after cord blood trans-
plantation. At 2 years, the cumulative incidence of relapse
was 46.35% (Figure 3A); it was 56% for patients who under-
went transplantation in CR1 and 32% for patients who
underwent transplantation in CR2 or more. In univariate
analyses, increased relapse risk was associated with (1) ﬁrst
complete remission (HR, 2.06; 95% CI, 1.02 to 4.19; P ¼ .045),
(2) secondary AML (HR, 2.2; 95% CI, 1.0 to 4.86; P ¼ .05);
and (3) 2 or more inductions course of chemotherapy toobtain ﬁrst complete remission (HR, 2.16; 95% CI,1.07 to 4.35;
P ¼ .036). There was no statistical association of number
of cord blood units transplanted with relapse incidence.
Other patient-, disease-, and transplantation-related factors
were not statistically associated with relapse. At time of
analysis, 30 patients died after relapse.
In a multivariate analysis, only patients having more than
1 induction course of chemotherapy to obtain remission had
a higher risk of relapsing after RIC UCBT (Figure 3B).
LFS and OS
Estimated LFS at 2 years was 35% (Figure 4A). It was 26%
for patients who underwent transplantation in CR1 and 48%
for patients who underwent transplantation in other
remission (HR, 1.79; 95% CI, 1.0 to 3.2; P ¼ .045) (Figure 4B).
Other factors associated with decreased LFS rate were sec-
ondary AML (HR, 1.99; 95% CI, 1.02 to 3.89; P ¼ .043) and
longer time from diagnosis to CR1 (HR, 1.05; 95% CI, 1.01 to
1.09; P ¼ .027). In a multivariate model, only patients with
secondary leukemia had decreased LFS (P¼ .043) (Figure 4C).
Estimated OS at 2 years was 44%. At last follow-up, 46
patients died; 30 of relapse and 16 of the transplantation-
related causes described above.
DISCUSSION
UCBT is considered an alternative option of allogeneic
HSCT for patients lacking an HLA-matched donor [23]. Even
if outcomes after single or double UCBT were compared with
those of HLA-identical siblings or unrelated donor recipients
after MAC regimen, delayed engraftment and toxicity leads
to a mortality rate of 34% to 57% [6-10].
In the last 6 years, UCBT has been frequently used in
adults with hematological malignancies, mainly after RIC.
Data from Eurocord registry show that two thirds of all adult
UCBT patients receive RIC and, of those, roughly two thirds
use double cord blood units (V. Rocha, Eurocord registry,
unpublished data).
In 2003, Barker et al. [24], on behalf of the University of
Minnesota, described the feasibility of UCBT using a RIC
regimen. Two types of regimen were used: 200 cGy TBI,
busulfan, ﬂudarabine, or 200 cGy TBI, cyclophosphamide,
and ﬂudarabine (TCF). The latter conditioning regimen was
associated with better engraftment rates. Later on, the same
group showed an NRM of 26% after UCBT with this condi-
tioning regimen [11,17,18]. In a registry-based analysis, the
Eurocord group has shown that outcomes of UCBT recipients
using TCF were associated with better outcomes when
compared with those using other regimens, with an NRM at
2 years of 12% for TCF and 51% for other regimens [25]. This
was conﬁrmed in a recent retrospective study that showed
2-year NRM of 19% in patients conditioned with TCF
compared with 52% for those receiving other regimens [18].
Recently, a multicenter prospective study reported the efﬁ-
cacy of double UCBT using TCF in 50 adult patients with
different hematological malignancies and disease status [26].
Cumulative incidence of engraftment was 94% and 1-year
NRM was 24% [26].
All the above studies show that RIC UCBT using single or
double cord blood units and TCF is feasible, with encouraging
results, and that NRM varies between 12% to 26% for adults
with heterogeneous diagnoses of malignant disorders and
disease status. However, it was not yet clear if outcomes after
RIC UCBT using a homogeneous conditioning (TCF) and
GVHD prophylaxis in patients with AML could be reproduc-
ible in a prospective multicenter trial.
Figure 3. (A) Cumulative incidence of relapse overall and (B) according to the number of previous inductions course to reach CR.
B. Rio et al. / Biol Blood Marrow Transplant 21 (2015) 445e453 451With our prospective, multicenter trial in France, wewere
able to demonstrate an NRM of 20% with the use of TCF and,
at the same time, evaluate other outcomes of RIC UCBT using
this regimen. Only patients with high-risk AML lacking a 10/
10 or 9/10 HLA unrelated donor and with comorbidities or
advanced agewere included.We showed that NRM at 2 years
was 20% after TCF UCBT in 79 AML patients in remission,
which is very similar to what has been observed after TCF
UCBT for other diseases.Figure 4. (A) Cumulative incidence of LFS overall, (B) according to statuWe found that a TNC dose >3.4  107/kg was an inde-
pendent risk factor for decreased NRM. This ﬁnding agrees
with what has been previously seen in the literature: cell
dose is an important risk factor associated with greater
engraftment and decreased NRM. The minimum cell dose for
UCBT in this protocol was pre-established at 3  107/kg
before freezing. We were able to ﬁnd a single unit for one
third of the patients, and the other two thirds of the patients
underwent transplantation with a double CB unit. In thiss (CR1 or not at transplantation), and (C) according to diagnosis.
B. Rio et al. / Biol Blood Marrow Transplant 21 (2015) 445e453452prospective trial, the number of CB units used (single or
double CB) was not associated with NRM. Interestingly,
another risk factor found to be associated with increased
NRM was major ABO incompatibility. In univariate analysis,
ABO major incompatibility was also associated with the
incidence of acute GVHD; however, the association was not
observed in the multivariate analysis. One could argue about
the possible rationale for this ﬁnding. In fact, it has been
demonstrated that the ABO glycosyltransferase-derived
peptides have the potential to function as minor histocom-
patibility antigens and elicit an in vitro T cell response [27].
ABO mismatch is well known to increase the risk of graft
failure in solid organ transplantation, although allogeneic
hematopoietic cell transplantation is successfully performed
across the ABO barrier [28]. Although reports suggested poor
disease-free survival with ABO-mismatch in UCBT recipients,
there are limited data on the impact of ABO mismatch on
GVHD after UCBT [25,29]. Despite the ﬁnding in our study
of the association of ABO major incompatibility with
acute GVHD in univariate analysis, we were not able to ﬁnd
any association in the multivariate model. More recent
studies analyzing UCBT recipients did not ﬁnd any associa-
tion with acute or chronic GVHD or NRM [30,31]. Therefore,
further investigations are needed to explain the reasons of
this association using a more homogeneous series of UCBT
after RIC. Other factors, such as number of HLA mismatches,
age, and comorbidity index did not affect NRM.
As expected, patients in our study who underwent
transplantation in CR1 had very high unfavorable risk of
AML, such as higher frequency of unfavorable cytogenetics,
secondary AML, FAB classiﬁcation (M5/M6/M7), and greater
number of induction courses of chemotherapy to achieve
CR1, compared with patients who underwent trans-
plantation in CR2 or more. These features can explain a
2-year relapse incidence of 56% for patients who underwent
transplantation in CR1. In a recent registry-based analysis,
relapse incidence was 44% after double UCBT using the TCF
regimen for patients with acute leukemias (AML and acute
lymphoblastic leukemia), including all disease statuses [18].
Patients who underwent transplantation in CR2 or in non-
remission had higher risk of relapse than patients who un-
derwent transplantation in CR1 [18].
In our analysis, incidence of relapse was not statistically
different in multivariate analysis according to disease status,
despite a higher incidence of relapse for CR1 patients. In fact,
the only factor increasing relapse incidence was the previous
number of induction chemotherapy courses to obtain ﬁrst
CR. LFS was also decreased in patients who underwent
transplantation in CR1; however, inmultivariate analysis, the
only factor associated with decreased LFS was the presence
of secondary AML. Those AML features of patients who un-
derwent transplantation in CR1 may explain the higher
incidence of relapse and decrease of LFS using this RIC
regimen.
In conclusion, UCBT using TCF is a feasible procedure for
patients with high-risk AML without an unrelated donor and
for whom MAC is contraindicated. Despite the decreased
NRM, the relapse incidence is quite high, and the LFS rate
decreased mainly for patients with high-risk AML. Strategies
including adding other drugs such as thiotepa, to this TCF
regimen or increasing the TBI dose, are under investigation
with very promising results [32]. Other strategies, such as
targeting leukemic cells with monoclonal antibodies, should
be further investigated to decrease the relapse incidence and
improve LFS without increasing toxicity after UCBT.ACKNOWLEDGMENTS
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